Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Whoops! Somebody left the water running.🤐
She goes up easy when these shorts cover on lower volume. They are day / overnight shorting hence messing up the SP. This BS has gotta stop!
So tell us, what is it like living in Hitler's old bunker? Do they charge much for rent?
Sharps Technology Enters Into a Five-Year Sales Agreement with Strategic U.S. Medical Products Company Creating +$5O Million in New Revenue for EU Facility
Definitive agreement sells out the 10mL SoloGard production capacity at Sharps’ manufacturing site in the EU and drives expansion to support the project’s growth in the future
Sharps’ portfolio of products provides attractive options to the U.S. Pharmaceutical Healthcare Industry as companies look for alternatives to Chinese-manufactured disposable syringes
Sharps has exceeded the product sales commitments for the EU-based facility made to investors in the June 2022 Shareholder Letter
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class prefillable and disposable syringe products, has successfully concluded negotiations and signed a contract with a prominent U.S.-based supplier of medical saline and water products to supply them with customized 10mL SoloGard syringes manufactured at Sharps’ facility in the EU. The customer initiated an evaluation of Sharps’ SoloGard product in light of the recent FDA recalls and tariffs imposed on Chinese supplied syringes. Their successful evaluation of the SoloGard syringes led to the execution of a five-year sales agreement that completely sells out the currently available manufacturing capacity for the 10mL SoloGard product. This transformative syringe program will drive the need for near-term expansion to support the current customer projects slated for the Hungary plant.
“Creating a strategic partnership with the customer and selling out production capacity at the Hungary plant for the next five years is a historic accomplishment for Sharps and the future success of the Company,” stated Robert Hayes, CEO of Sharps Technology. “The collaboration creates a five-year sales agreement for at least 500 million syringes and essentially consumes the current available manufacturing capacity for Sharps’ 10mL SoloGard disposable syringe. This project also provides a clear path for near-term revenue for our company beginning in Q4 2024, with a phased ramp up into 2025.”
Filippo Filippi, General Manager of the SafeGard manufacturing facility, is pleased that his plant is delivering on commitments made by Sharps leadership in 2022. “We have been driven to bring our innovative syringes to the U.S. healthcare market,” says Filippi. “After two years of dedicated efforts, I am excited for this five-year commitment for the 500 million units, starting with the 10mL SoloGard shipments in November of this year. Equally as important, this sales agreement will help provide a solid foundation for the continued expansion of Sharps’ European division in Hungary.”
The Company believes that the need for innovative injection solutions continues to grow rapidly as injectables are the first choice for therapies as diverse as vaccines, biologics, weight loss and maintenance, ophthalmic and cosmetic applications, gene therapies, and diabetes and inflammatory disease management. As a result of this market growth and the impact of the tariffs, recalls, and quality issues with Chinese supplied syringes, Sharps is seeing increasing levels of interest and potential demand for its high-quality smart safety syringe products. Specializing in the development and manufacturing of innovative drug delivery systems, Sharps’ SecureGard and SoloGard product lines focus on low waste and ultra-low waste syringe technologies that also incorporate active safety features, as well as World Health Organization accredited re-use prevention measures.
About Sharps Technology
Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry. The Company’s product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features. Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The Company has a manufacturing facility in Hungary and is partnering with Nephron Pharmaceuticals to expand its manufacturing capacity in the U.S. For more information about Sharps Technology, please visit the website at: http://sharpstechnology.com.
FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements”. Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” “poised” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult t
Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results
Expands AI/ML driven offering to include novel oncology biomarker discovery to predict patient outcomes and drug response in oncology
Biomarker discovery market estimated by third party research to be $51.5 billion in 2024
PITTSBURGH, July 25, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that it is expanding its AI/ML driven drug discovery platform to pursue discovery of novel biomarkers that can be used to predict patient outcomes and drug response in oncology.
Predictive Oncology’s biomarker discovery initiative stems, in part, from results obtained in the retrospective ovarian cancer study with UPMC Magee-Womens Hospital, which were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. In that study, Predictive Oncology successfully developed muti-omic machine learning models that identified key features that could more accurately predict both short-term (two-year) and long-term (five-year) survival outcomes among ovarian cancer patients as compared to clinical data alone. Through this process, Predictive Oncology obtained and analyzed data that supports novel ovarian cancer biomarker discovery and development that will be further explored both independently and in partnership with biopharma companies.
“We have already demonstrated the capabilities of our active machine learning platform to selectively utilize our diverse patient samples preserved in our biobank to predict responses to drugs with a very high degree of accuracy,” said Arlette H. Uihlein, MD, SVP, Translational Medicine and Drug Discovery and Medical Director at Predictive Oncology. “We are now taking this one step further by applying state-of-the-art deep learning approaches for biomarker discovery related to both patient overall survival (OS) and drug response, which can be done with existing resources. Our platform enables us to apply deep learning to the correct patient cohorts and accelerate the initial stages of biomarker discovery.”
“We believe the identification of novel cancer biomarkers represents the next significant opportunity for the application of our platform, which leverages the substantial value inherent in the diversified patient samples and data that we possess, as well as additional potential revenue streams for our company. Our technology has broad applicability, including the development of a clinical decision support tool to screen for clinical trial enrollment, and to inform subsequent drug discovery and development,” stated Raymond Vennare, Chief Executive Officer of Predictive Oncology. “These capabilities extend well beyond ovarian cancer and can be used in the discovery of biomarkers for other cancer types as well, and we look forward to further validating these capabilities through development collaborations with leading biopharmaceutical partners and healthcare networks.”
The total biomarker discovery market is estimated by third party research to be $51.5 billion in 2024.1
Predictive Oncology also announced today the release of a new white paper that discusses its biomarker discovery capabilities in greater detail. The white paper can be accessed at: https://predictive-oncology.com/blog/BiomarkerDiscovery.
About Predictive Oncology
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early biomarker and drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Together with the company’s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry’s broadest AI-based drug discovery solutions, further complimented by its wholly owned CLIA lab and GMP facilities. Predictive Oncology is headquartered in Pittsburgh, PA.
Investor Relations Contact
Tim McCarthy
LifeSci Advisors, LLC
tim@lifesciadvisors.com
Forward-Looking Statements:
Certain matters discussed in this release contain forward-looking statements. These forward- looking statements refl
Thank you for this great posting! yes sir a joint PR is where it's at. Most likely need Honda to approve that in writing.
Wow, a guy from NASA is posting here! Very impressive!
$HYSR new 52-week high .026
Here you go Falcon1 = SunHydrogen Announces Joint Development Agreement with Honda R&D Co., LTD
CORALVILLE, IA – July 24, 2024 – SunHydrogen, Inc. (OTCQB: HYSR), the developer of a breakthrough technology to produce renewable hydrogen using sunlight and water, today announced that it has entered into a joint development agreement with Honda R&D Co., LTD.
SunHydrogen’s innovative solar hydrogen technology uses abundant and low-cost materials, requires no external power other than sunlight, and is designed with scalability in mind. Its core components include a substrate, photovoltaic layers, and catalysts that integrate to split water molecules into green hydrogen and oxygen.
Working in collaboration with SunHydrogen, Honda R&D Co. will use its industry-leading manufacturing and design capabilities to jointly develop an installation-ready hydrogen panel for safe and efficient hydrogen production and collection.
The principal objective of the joint development agreement between Honda and SunHydrogen is to synergize efforts toward the application of SunHydrogen’s innovative solar-hydrogen module technology for cost-effective green hydrogen.
Honda R&D Co. engages in the research and development of emerging technologies and products that can bring value to Honda as the company looks to reach carbon neutrality for all products and operations by 2050.
About SunHydrogen, Inc.
SunHydrogen is developing breakthrough technologies to make, store and use green hydrogen in a market that Goldman Sachs estimates to be worth $12 trillion by 2050. Our patented SunHydrogen Panel technology, currently in development, uses sunlight and any source of water to produce low-cost green hydrogen. Like solar panels that produce electricity, our SunHydrogen Panels will produce green hydrogen. Our vision is to become a major technology supplier in the new hydrogen economy. By developing, acquiring and partnering with other critical technologies, we intend to enable a future of emission-free hydrogen production for all industrial applications such as fertilizer and petroleum refining as well as fuel cell applications for mobility and data centers. To learn more about SunHydrogen, please visit our website at www.SunHydrogen.com.
Safe Harbor Statement
Matters discussed in this press release may contain forward-looking statements. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. Forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company's reports filed with the Securities and Exchange Commission. Forward-looking statements contained herein are applicable only as of the date on which they are made, and the Company does not assume any obligation to update any forward-looking statements, except as may be required under applicable law.
Press Contact
info@sunhydrogen.com
Visit our website
SunHydrogen, Inc.
2500 Crosspark Road
Coralville, Iowa
USA
Powered by Squarespace
Unsubscribe
Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment
Treatment of pre-clinical subjects showed cognitive benefits that suggest HT-ALZ's mode of action may involve a reduction in brain inflammation, thereby improving cognitive outcomes for Alzheimer's patients.
HT-ALZ's pre-clinical significance lies in its ability to demonstrate marked cognitive improvement and quality of life for subjects suffering from Alzheimer's disease
The pre-clinical research shows compelling evidence of HT-ALZ's capacity to improve memory tasks related to the hippocampus and sensorimotor gating, showcasing an important step forward in Alzheimer's disease treatment.
NEW YORK, July 24, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has signed an agreement with LTS Therapy Systems, LLC ("LTS"), to develop and manufacture the HT-ALZ oral film prototype. HT-ALZ is being developed as a novel therapeutic solution for Alzheimer's Disease based on its exciting preclinical results released earlier this year. HT-ALZ's pre-clinical significance lies in its ability to restore cognitive functions and improve quality of life for subjects suffering from Alzheimer's disease.
"Hoth is excited to announce this partnership and the next milestone in our development of HT-ALZ," stated Robb Knie, Chief Executive Officer. "We are leveraging LTS's expertise to develop and manufacture the oral film prototypes needed for this particular population and leveraging our positive preclinical results to advance our Alzheimer's therapeutic ."
The HT-ALZ prototype development and manufacturing work by LTS will be used to support a future Investigational New Drug (IND) Application to initiate clinical trials. For more information on Hoth Therapeutics and our innovative approach to Alzheimer's disease treatment with HT-ALZ, please visit https://hoththerapeutics.com.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .
2 PR's in a row! Very unusual but here it is: SunHydrogen Announces Joint Development Agreement with Honda R&D Co., LTD
CORALVILLE, IA – July 24, 2024 – SunHydrogen, Inc. (OTCQB: HYSR), the developer of a breakthrough technology to produce renewable hydrogen using sunlight and water, today announced that it has entered into a joint development agreement with Honda R&D Co., LTD.
SunHydrogen’s innovative solar hydrogen technology uses abundant and low-cost materials, requires no external power other than sunlight, and is designed with scalability in mind. Its core components include a substrate, photovoltaic layers, and catalysts that integrate to split water molecules into green hydrogen and oxygen.
Working in collaboration with SunHydrogen, Honda R&D Co. will use its industry-leading manufacturing and design capabilities to jointly develop an installation-ready hydrogen panel for safe and efficient hydrogen production and collection.
The principal objective of the joint development agreement between Honda and SunHydrogen is to synergize efforts toward the application of SunHydrogen’s innovative solar-hydrogen module technology for cost-effective green hydrogen.
Honda R&D Co. engages in the research and development of emerging technologies and products that can bring value to Honda as the company looks to reach carbon neutrality for all products and operations by 2050.
About SunHydrogen, Inc.
SunHydrogen is developing breakthrough technologies to make, store and use green hydrogen in a market that Goldman Sachs estimates to be worth $12 trillion by 2050. Our patented SunHydrogen Panel technology, currently in development, uses sunlight and any source of water to produce low-cost green hydrogen. Like solar panels that produce electricity, our SunHydrogen Panels will produce green hydrogen. Our vision is to become a major technology supplier in the new hydrogen economy. By developing, acquiring and partnering with other critical technologies, we intend to enable a future of emission-free hydrogen production for all industrial applications such as fertilizer and petroleum refining as well as fuel cell applications for mobility and data centers. To learn more about SunHydrogen, please visit our website at www.SunHydrogen.com.
Safe Harbor Statement
Matters discussed in this press release may contain forward-looking statements. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. Forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company's reports filed with the Securities and Exchange Commission. Forward-looking statements contained herein are applicable only as of the date on which they are made, and the Company does not assume any obligation to update any forward-looking statements, except as may be required under applicable law.
Press Contact
info@sunhydrogen.com
Visit our website
SunHydrogen, Inc.
2500 Crosspark Road
Coralville, Iowa
USA
Powered by Squarespace
Unsubscribe
I must be dreaming!
We all can LOL all we want but when you look at the scope of this being a public Company, what MR Young did is brilliant! I had told this to a newbie and scared him off a couple of months ago but here is HYSR just a tad above 01 and it's assigned "penny stock exempt"! You show me another OTC Company with this criteria trading even at .25 and I will buy you lunch. Also, HYSR has 40 million dollars in the bank. When you think about all this and realize that the CEO made a Kings ransom without the stress of being a CEO trying to build a Company. He has no employees only consultants. These high-strung executives elsewhere killing themselves having ulcers and heart attacks while MR Young sits by his pool all year and might take a working vacation to Germany or Asia.
It's all legal too. Not a thing done wrong. Just hope MR young didn't get all stuck up like so many that have become so wealthy. lol
You make excellent points here strawpatch. This entire thing ran its course. They need to scrap it and move into being the 1st Public Company to invent time travel/time machine. They can start the prototype now and I guarantee there will be plenty of gullible investors scrambling to buy. Take it to NASDAQ it would be $1,000 per share! :)
15 years and not a measly penny of revenue and yet the Company has a 5 million dollar high-yielding certificate of deposit going on 2 years. Stock is more boring than watching paint dry.
Then let me rephrase what I had said. = This stock is a travesty. It's a travesty of a mockery of a sham of a mockery of two mockeries of a sham
Then let me rephrase what I had said. = This stock is a travesty. It's a travesty of a mockery of a sham of a mockery of two mockeries of a sham
My next buy-in price will be in the $1.25 range give or take a dime.
This is why I asked you to get a paid membership so you can PM.
You must have moved to a country that has no extradition treaty. SMART!
SunHydrogen Announces Agreement with CTF Solar GmbH, Global Innovator of Thin Film Solar Cell Modules, to Accelerate Production of Green Hydrogen Panels
CORALVILLE, IA – July 23, 2024 – SunHydrogen, Inc. (OTCQB: HYSR), the developer of a breakthrough technology to produce renewable hydrogen using sunlight and water, today announced that the Company has entered into a technology collaboration agreement with CTF Solar GmbH to integrate CTF’s solar cell modules into SunHydrogen’s technology for green hydrogen production.
In a recent letter to shareholders, SunHydrogen’s CEO Tim Young detailed the advantages of pursuing this strategy in parallel with the Company’s nanoparticle technology.
Over the past eight months, SunHydrogen has successfully adapted CTF Solar's commercial solar cell module design to create a 100 cm² hydrogen module that facilitates hydrogen production with minimal modifications to the existing manufacturing process. This strategic adaptation enhances the photovoltaic elements to achieve optimal voltages and currents, essential for efficient hydrogen generation. Furthermore, SunHydrogen is leading efforts to integrate catalysts and is collaborating closely with CTF Solar to implement stabilization coatings, ensuring improved performance and durability of the modules.
Through the agreement, SunHydrogen and CTF Solar will initiate the production of hydrogen modules for a pilot demonstration involving 50 1m² green hydrogen panels. This collaboration will evaluate the performance, cost-efficiency and operational functionality of these modules at a systems level. Soon, SunHydrogen plans to announce an industrial partner for development of housing units and essential infrastructure necessary for scaling up to commercial production.
With a proud history spanning decades of innovation, CTF Solar is not only a technical partner, but also a robust industrial partner capable of scaling operations globally. Located in Dresden, Germany, CTF Solar is managed by pioneering German photovoltaic engineers and owned by China Triumph International Engineering Co., Ltd. (CTIEC), a top 200 global design and engineering company. CTIEC is part of the CNBM Group, a Global Fortune 500 company and the largest building materials supplier in Asia.
About SunHydrogen, Inc.
SunHydrogen is developing breakthrough technologies to make, store and use green hydrogen in a market that Goldman Sachs estimates to be worth $12 trillion by 2050. Our patented SunHydrogen Panel technology, currently in development, uses sunlight and any source of water to produce low-cost green hydrogen. Like solar panels that produce electricity, our SunHydrogen Panels will produce green hydrogen. Our vision is to become a major technology supplier in the new hydrogen economy. By developing, acquiring and partnering with other critical technologies, we intend to enable a future of emission-free hydrogen production for all industrial applications such as fertilizer and petroleum refining as well as fuel cell applications for mobility and data centers. To learn more about SunHydrogen, please visit our website at www.SunHydrogen.com.
Safe Harbor Statement
Matters discussed in this press release may contain forward-looking statements. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. Forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company's reports filed with the Securities and Exchange Commission. Forward-looking statements contained herein are applicable only as of the date on which they are made, and the Company does not assume any obligation to update any forward-looking statements, except as may be required under applicable law.
Press Contact
info@sunhydrogen.com
Visit our website
SunHydrogen, Inc.
2500 Crosspark Road
Coralville, Iowa
USA
Powered by Squarespace
Unsubscribe
CEO Andrew Toy posted this on Linkedin last night
The question of when a surgeon should retire has been debated for decades.
Aging brings physical and cognitive changes that can impact a surgeon's performance. Yet, no federally mandated retirement age exists for surgeons in the U.S, leaving this an unfortunate gray area filled with complex considerations.
Aging can lead to a decline in vision, dexterity, and cognitive skills, which are critical for performing surgery. Anecdotes and studies suggest that older surgeons may struggle with new technologies or more complex procedures. For example, some older surgeons continue performing outdated techniques due to their remoteness from recent education and advancements. This can lead to increased risks during surgery, as seen in cases where hospitals have had to silently compensate for an aging surgeon's declining skills until a serious incident occurs.
Additionally, if you read the linked paper, there have been instances where those close to the surgeon feel the need to protect them by shielding their performance or even boosting it. For example, extra staff may be allocated, or special preparations made, to mitigate the risks posed by an aging superstar surgeon’s declining abilities. This form of "protection" can inadvertently mask the underlying issue and delay necessary interventions.
However, experience and wisdom gained over years also can’t be discounted. Many older surgeons offer unparalleled expertise and judgment honed over decades, especially when treating rarer conditions. The challenge is balancing the value of this experience with the potential risks posed by physical and cognitive decline.
Mandatory retirement, as seen in other professions like aviation, is one approach but presents a risk of running afoul of age discrimination laws. Instead, some suggest implementing regular, comprehensive evaluations to ensure surgeons maintain the necessary skills. Yet, the medical community has not reached a consensus on how to effectively assess and address this issue.
The key is fostering a culture where surgeons plan for retirement and transition to roles where their experience remains valuable, such as teaching or mentoring. By doing so, we can respect the contributions of aging surgeons while ensuring patient safety remains paramount.
At the end of the day it comes down to patient risk tolerance and confidence. Everyone wants to know they’re in good hands.
https://lnkd.in/gmwnwqbU
hashtag#Healthcare hashtag#HealthyAging hashtag#PatientSafety hashtag#MedicalEthics hashtag#physician hashtag#retirement
Activate to view larger image,
Image preview
Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program
BELLEVUE, Wash.--(BUSINESS WIRE)-- Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today that it has received notice of the commencement of disbursement for the complete monetization of a Standby Letter of Credit (“SBLC”). The initial disbursement represents the first payment as per the arrangement creating a release of lien resulting in the subsequent final advance to the Company. With this initial disbursement the Company expects final distribution to follow on or before August 2. As previously reported, the Company entered into an application for the monetizing program whereby the Company is projected to receive gross funding proceeds of approximately $78 million under the SBLC monetization program.
Robert Mattacchione, Novo’s CEO and Board Chairman, stated, "The commencement of distribution marks the first payments in the process of full monetization of the SBLC. This step will now lead us to receiving our full expected payout as identified in the transaction documents. We look forward to engaging in our intended initiatives.”
About Novo Integrated Sciences, Inc.
Novo Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation. Novo offers an essential and differentiated solution to deliver, or intend to deliver, these services and products through the integration of medical technology, advanced therapeutics, and rehabilitative science.
We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective healthcare distribution.
The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers:
First Pillar: Service Networks. Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities.
Second Pillar: Technology. Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner thus expanding the reach and availability of the Company’s services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral based healthcare services, including the patient’s home.
Third Pillar: Products. Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population. The Company’s science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions.
Innovation through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting-edge advancement in patient-first platforms.
For more information concerning Novo Integrated Sciences, please visit www.novointegrated.com.
Twitter, LinkedIn, Facebook, Instagram, YouTube
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, or the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as "believe," “intend,” "expect," "anticipate," "plan," "potential," "continue," or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks, and uncertainties are discussed in Novo’s filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown uncertainties and other factors which are, in some cases, beyond Novo’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Novo’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Novo assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The contents of any website referenced in this press release are not incorporated by reference herein.
https://cts.businesswire.com/ct/CT?id=bwnews&sty=20240718621664r1&sid=acqr8&distro=nx&lang=en
View source version on businesswire.com: https://www.businesswire.com/news/home/20240718621664/en/
Chris David, COO
Novo Integrated Sciences, Inc.
chris.david@novointegrated.com
(888) 512-1195
Source: Novo Integrated Sciences, Inc.
© Copyright Business Wire 2024
Back to News Headlines
Other Financial Information
Where would we be if not for these scams? lol
I'm in CLOV for the long term. My price target is $10.00
OT: $ATXG is awaiting the next China pump. only because you are a goofy doggie 🥰
Your target price was hit a couple of days ago. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174701605
Public Float on July 15, 2024
Common Stock, 4,121,254
That does not compute Will Robinson. :)
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing Phase 1/2 clinical trial of CFT1946, a novel BiDAC™ degrader in mutant BRAF V600 solid tumors, will be presented as a mini oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 taking place September 13 – 17, 2024 in Barcelona, Spain.
Details of the presentation are as follows:
Title: Preliminary Results from a Phase 1 Study of CFT1946, a Novel BIDAC Degrader in Mutant BRAF V600 Solid Tumors
Presentation Date and Time: Saturday, September 14, 2024, 2:45 – 2:50 CEST
Final Publication Number: 612MO
Session Category: Mini oral session
Session Title: Developmental therapeutics
Location: Oviedo Auditorium – Hall 3
Presenter: Maria Vieito, M.D., Msc (Barcelona, Spain, La Coruña)
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
About CFT1946
CFT1946 is an orally bioavailable BiDAC™ degrader designed to be potent and selective against BRAF V600X mutant targets. In preclinical studies, CFT1946 is active in vivo and in vitro in models with BRAF V600E driven disease and in models resistant to BRAF inhibitors. CFT1946 is currently in a Phase 1 dose escalation study in BRAF V600X mutant solid tumors including colorectal cancer, melanoma and non-small cell lung cancer. More information about this trial may be accessed at www.clinicaltrials.gov (identifier: NCT05668585).
Strong close in after-hours trading!!!!😁
Thank you! I agree and I'm not in a rush. :)
The shorts got wind of something in the works otherwise why all the covering? If the CEO has something juicy and meaty to announce then IMHO the shares go to the $18 -$20 mark on a sneeze. This is a great poker game and the question is who has the best hand or is it all a bluff?
The accumulation here over the past several weeks has been outstanding!
Here I am lol.
Old 52-week high smashed! Love your post!🥰
LMFAO @ butt PLUG comment! And that is exactly where it belongs!
I love your enthusiasm! We are heading in that direction.
Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic
Agreement enhances Company’s intellectual property portfolio
SARASOTA, FL, July 16, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into an exclusive global license agreement to further develop, manufacture, and commercialize its Alzheimer’s drug SPC-14. Silo intends to utilize the FDA’s streamlined 505(b)(2) pathway for SPC-14, which would shorten clinical timelines and reduce drug development costs.
“In our view, our exclusive license for SPC-14 gives us the potential to meet a large unmet medical need. If approved, we believe SPC-14 could bring hope and relief for many families and patients. Early pre-clinical studies have shown stress reduction and cognitive improvement,” said Silo CEO Eric Weisblum.
Silo Pharma recently announced a similar exclusive license agreement for its lead drug candidate, SPC-15, an intranasal treatment for stress-induced affective disorders and PTSD.
The global Alzheimer’s disease therapeutics market size is forecasted to exceed $30.8 billion by 2033, with a CAGR of 18.8% from 2024 to 2033 1 . Rising prevalence of the disease in the expanding elderly population and advancements in neurological research are expected to drive market growth.